Zoe Craig on Muck Rack

Zoe Craig

London
As seen in: Wiley Online Library, SheKnows, EClinicalMedicine, English Heritage Magazine, Londonist, Netmums, TNT Magazine (UK)
Journalist, editor, writer, talker. Content Producer at English Heritage 🏰
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zoe

Contact Zoe, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Refreshing Play Fountains In London For Cooling Down This Summer

|
By Zoe Craig
| Londonist Verified
By Zoe Craig Last Updated 26 May 2026 Zoe Craig Refreshing Play Fountains In London For Cooling Down This Summer In desperate need of somewhere to cool down? Read our guide to how to survive a heatwave in London. Jeppe Hein's Disappearing Rooms are a staple of hot days in London. Photo: Shutterstock Indulge your inner kid by splashing around in one of these refreshing play fountains — ideal for cooling off in a London heatwave. Just remember to pack a towel and spare clothes.
Open in Who Shared Issue with article?

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

|
By Byers L.A, Zoe Craig, Jonathan Wadsley, Lucy Wall
| EClinicalMedicine Verified
Summary Background The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment.
Open in Who Shared Issue with article?

Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials

|
By James R. Platt, Zoe Craig, David Cairns, James C Glasbey
| Wiley Online Library Verified
STUDY PROTOCOLS Abstract Aim FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp) chemotherapy was associated with greater 2-year disease-free survival (DFS) when compared with proceeding straight to surgery (STS). There is now a need to refine the use of NAC and identify those most likely to benefit.
Open in Who Shared Issue with article?
See all 337 licensed articles (340 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified